In 2014, an article by AM Coker et al. titled “Outcomes of robotic-assisted transhiatal esophagectomy for esophageal cancer after neoadjuvant chemoradiation.” in Journal of Laparoendoscopic & Advanced Surgical Techniques aimed to “determine if [robotic-assisted transhiatal esophagectomy (RATE)] could be performed safely with good outcomes for esophageal cancer in a more recent series of patients”.

The authors write “This was a retrospective review of patients with adenocarcinoma of the distal esophagus or gastroesophageal junction who underwent RATE between November 2006 and November 2012 at a single tertiary-care hospital.”  In all, the study consisted of 23 patients – 20 men and 3 women.

“Complications included seven strictures, two anastomotic leaks, and two pericardial/pleural effusions requiring drainage. One patient required pyloroplasty 3 months after esophagectomy.” And sadly, “One patient died from pulmonary failure 21 days after surgery (30-day mortality rate of 4%).”

Due to the fact that this procedure is indeed quite complicated, these researchers purport that “RATE can be performed safely with good oncologic outcomes following neoadjuvant chemoradiation in patients with esophageal cancer”.  What is important however, is that patients be informed of the risk for complications associated with any procedure.

Since Da Vinci, the manufacturer of many popular robotic surgery systems, has failed time and again to make the risk rates clear to users, a number of Da Vinci surgical robots lawsuits have been filed.  If you or a loved one underwent robot-assisted surgery and suffered complications, you too may be entitled to significant financial compensation for your injuries.  For a free, no-obligation case consultation, contact our team of surgical robot lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.

Call today and see how we can help.

(855) 452 – 5529